Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.
Paolo PiattiYap Ching ChewMichiko SuwotoTaikun YamadaBenjamin JaraXi-Yu JiaWei GuoSaum GhodoussipourSiamak DaneshmandHamed AhmadiJeffrey RiceJeffrey BhasinFaith HollowayYvonne TsaiYoshitomo ChiharaGangning LiangPublished in: Clinical epigenetics (2021)
Highly sensitive detection of BC in urine samples is possible using Bladder CARE. The low LOD of the test and the measurement of epigenetic biomarkers make Bladder CARE a good candidate for the early detection of BC and possibly for the routine screening and surveillance of BC patients. Bladder CARE and the at-home urine sample collection system have the potential to (1) reduce unnecessary invasive testing for BC (2) reduce the burden of surveillance on patients and on the healthcare system, (3) improve the detection of early stage BC, and (4) allow physicians to streamline the monitoring of patients.
Keyphrases
- end stage renal disease
- healthcare
- ejection fraction
- early stage
- newly diagnosed
- palliative care
- chronic kidney disease
- gene expression
- prognostic factors
- dna methylation
- quality improvement
- risk factors
- climate change
- high resolution
- label free
- loop mediated isothermal amplification
- clinical practice
- neoadjuvant chemotherapy
- fluorescent probe
- single molecule